BackgroundIn addition to HPV, high parity and hormonal contraceptives have been associated with cervical cancer (CC). However, most of the evidence comes from retrospective case-control studies. The aim of this study is to prospectively evaluate associations between hormonal factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC).Methods and findingsWe followed a cohort of 308,036 women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a questionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS cases were reported. In a nested case-control study, the sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivariate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). The cohort analysis showed that number of full-term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS and ICC (HR = 1.6 and HR = 1.8 respectively for ≥ 15 years versus never use). Ever use of menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%CI: 0.4-0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices (IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all cases and HPV seropositive controls yielded similar results, revealing a significant inverse association with IUD for combined CIN3/CIS and ICC (OR = 0.7).ConclusionsEven though HPV is the necessary cause of CC, our results suggest that several hormonal factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.
hormonal contraceptives cervical cancer risk, oral contraceptives and cervical cancer, parity cervical cancer risk, IUD cervical cancer prevention, hormonal factors HPV cervical cancer, birth control pills cervical intraepithelial neoplasia, menopausal hormone therapy cervical cancer, contraceptive methods cancer risk, EPIC cohort cervical cancer, hormonal risk factors CIN3
Cite this article
Roura, E., Travier, N., Waterboer, T., de Sanjosé, S., Bosch, F. X., Pawlita, M., Pala, V., Weiderpass, E., Margall, N., Dillner, J., Gram, I. T., Tjønneland, A., Munk, C., Palli, D., Khaw, K., Overvad, K., Clavel-Chapelon, F., Mesrine, S., Fournier, A., . . . Castellsagué, X. (2016). The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. *PloS one*, *11*(1), e0147029. https://doi.org/10.1371/journal.pone.0147029
Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One. 2016;11(1):e0147029. doi:10.1371/journal.pone.0147029
Roura, Esther, et al. "The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort." *PloS one*, vol. 11, no. 1, 2016, pp. e0147029.
Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to infections such as HIV-1, unlike the injectable contraceptive norethisterone en...
Contraception/Comparison > FABM vs Hormonal > Side EffectsReproductive Endocrinology > Progesterone > Clinical EffectsContraception/Comparison > Side Effects > Hormonal Contraception
The glucocorticoid receptor (GR) regulates several physiological functions, including immune function and apoptosis. The HIV-1 virus accessory protein, viral protein R (Vpr), can modulate the transcri...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side Effects
Anastasiou E et al., 2022
Open Access
Contraception
ObjectiveStudies on the effect of long-term use of combined oral contraceptives (COCs) on cervical dysplasia and/or cancer risk have been inconsistent. Less is known about the effects of other forms o...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side Effects
Yonis H et al., 2025
Open Access
BMJ (Clinical research ed.)
Objective: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction. Design: Real-world, nationwide, prospective ...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence